ClinicalTrials.gg

Program

insulin icodec

Also written as “Insulin icodec”, “Insulin Icodec” and “IcoSema”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Novo Nordisk.

Furthest: phase 4, since Aug 1, 202530 company-led studies, 2 open or runningNext primary completion: Jan 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk302 open or runningphase 4since Aug 1, 2025Mar 8, 2013Jan 25, 2027phase 3 · NCT07076199

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Mar 8, 2013.

  1. Oct 8, 20203 phase 1 studies in Diabetes Mellitus, Type 2NCT04582448, NCT04582435, NCT04597697
  2. Feb 17, 20212 phase 3 studies in Diabetes Mellitus, Type 2NCT04760626, NCT04770532
  3. Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
  4. Apr 16, 2021Phase 3 study in Diabetes Mellitus, Type 1NCT04848480 · 582 enrolled · United States, Austria, Canada and more
  5. Apr 22, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04857398 · 24 enrolled · China
  6. May 6, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04880850 · 582 enrolled · United States, Belgium, India and more
  7. Apr 24, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05352815 · 1,291 enrolled · United States, Australia, Belgium and more
  8. Jun 23, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05435677 · 20 enrolled · China
  9. Mar 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05790681 · 18 enrolled · United States
  10. Apr 3, 20232 phase 3 studies in Diabetes Mellitus, Type 2NCT05813912, NCT05823948
  11. Feb 23, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06288412 · 30 enrolled · Austria
  12. Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
  13. Jul 14, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT07076199 · 877 enrolled · United States, Australia, Canada and more
  14. Aug 1, 2025Phase 4 study in Diabetes Mellitus, Type 2NCT07112339 · 586 planned · Canada, Germany, Italy

Ahead

  1. Jan 25, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07076199
  2. Mar 23, 2028Primary completion: phase 4 study in Diabetes Mellitus, Type 2NCT07112339

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

All 30 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07112339Diabetes Mellitus, Type 2 · Canada, Germany, Italy4RecruitingMar 23, 2028586
NCT07076199Diabetes Mellitus, Type 1 · United States, Australia, Canada and more3Active, not recruitingJan 25, 2027877
NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more3CompletedMay 8, 2025412
NCT06288412Diabetes Mellitus, Type 2 · Austria1CompletedMar 10, 202530
NCT05823948Diabetes Mellitus, Type 2 · United States3CompletedMar 6, 202451
NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more3CompletedApr 14, 2025148
NCT05790681Diabetes Mellitus, Type 2 · United States1CompletedFeb 8, 202418
NCT05435677Diabetes Mellitus, Type 2 · China1CompletedApr 25, 202320
NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more3CompletedMar 19, 20241,291
NCT04880850Diabetes Mellitus, Type 2 · United States, Belgium, India and more3CompletedJun 16, 2022582
NCT04857398Diabetes Mellitus, Type 2 · China1CompletedApr 6, 202224
NCT04848480Diabetes Mellitus, Type 1 · United States, Austria, Canada and more3CompletedApr 28, 2022582
NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more3CompletedJun 23, 2022588
NCT04770532Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more3CompletedJan 27, 2022526
NCT04760626Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more3CompletedAug 12, 20221,085
NCT04597697Diabetes Mellitus, Type 2 · Czechia, Slovakia1CompletedMar 24, 202225
NCT04582448Diabetes Mellitus, Type 2 · Germany1CompletedSep 27, 202125
NCT04582435Diabetes Mellitus, Type 2 · Austria1CompletedApr 22, 202246
NCT04460885Diabetes Mellitus, Type 2 · United States, Croatia, India and more3CompletedMay 29, 2022984
NCT03951805Diabetes Mellitus, Type 2 · United States, Croatia, Germany and more2CompletedDec 12, 2019205
NCT03945656Diabetes Mellitus, Type 2 · Austria1CompletedSep 27, 202143
NCT03922750Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more2CompletedDec 19, 2019154
NCT03789578Diabetes Mellitus, Type 2 · Germany1CompletedOct 10, 201930
NCT03766854Diabetes Mellitus, Type 1 · Japan1CompletedDec 9, 201924
NCT03751657Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more2CompletedDec 16, 2019247
NCT03723785Diabetes Mellitus, Type 2 · Germany1CompletedSep 6, 201958
NCT03723772Diabetes Mellitus, Type 1 · Germany1CompletedJun 26, 202066
NCT02964104Diabetes Mellitus · Germany1CompletedDec 12, 201750
NCT02148861Diabetes Mellitus · Germany1CompletedJun 1, 201549
NCT01809184Diabetes Mellitus · Germany1CompletedSep 6, 201384

How it is read

Names in the registry

  • “Insulin icodec”, 18 entries
  • “insulin icodec”, 5 entries
  • “Insulin Icodec”, 4 entries
  • “IcoSema”, 1 entry
  • “NNC0148-0287”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.